Dr. Yeh is an Associate in the Southern California office of Fish & Richardson. He has extensive hands on experience in small molecule chemical synthesis, bio-conjugation, preclinical drug development, medical imaging agents/tracers, and materials synthesis. He leverages his strong research experience and deep scientific acumen to help clients achieve superior results efficiently. He is particularly effective at communicating with inventors and experts on their technical wavelength and at quickly grasping complex technical concepts. His practice focuses on prosecution, counseling, and litigation in pharmaceuticals, chemical synthesis, biotechnology, sequencing technology, materials science, and medical devices.
Dr. Yeh was a Summer Associate and Diversity Fellow with the firm in 2010 and 2011. Prior to joining the firm, he was a senior analyst for a scientific strategy consulting firm and a research scientist at the medical imaging division of Siemens Medical Solutions. He previously co-chaired Fish & Richardson’s associate committee.
May 9, 2018
Robert Yeh Authors article "Precedential Decisions at the PTAB: An Endangered Species?" published in the Chicago-Kent Journal of Intellectual Property
Fish Litigation Blog
December 11, 2014
Mistakenly-Filed Statutory Disclaimer Cannot be Withdrawn Using Certificate of Correction, and PTO Not Required to Exercise Inherent Authority to Withdraw It
Authors: Robert M. Yeh, Ph.D., Craig Countryman
August 29, 2014
If ANDA is Silent on Infringement, then Infringement is Assessed Based on the Product Likely to Be Sold; Courts Have Discretion to Consider Post-Trial ANDA Amendments
August 29, 2014
Infringement Analysis Under §271(e) Focuses On The Product That Is Likely To Be Sold Following ANDA Approval, Not